IGFBP1 and familial pancreatic carcinoma: In phase 3 clinical trial of 602 patients with advanced metastatic pancreatic cancer for analyzing and comparing the therapeutic efficacy of the combination of gemcitabine with bevacizumab and combination of gemcitabine with placebo, IGFBP1 was found as one of the potential predictive prognostic markers [91].